CHEMOCENTRYX INC's ticker is CCXI and the CUSIP is 16383L106. A total of 86 filers reported holding CHEMOCENTRYX INC in Q4 2017. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $166,000 | -72.9% | 24,500 | -62.8% | 0.00% | -75.0% |
| Q2 2019 | $613,000 | -13.8% | 65,890 | +28.7% | 0.01% | -20.0% |
| Q1 2019 | $711,000 | +34.2% | 51,190 | +22.1% | 0.01% | +25.0% |
| Q3 2018 | $530,000 | -8.0% | 41,908 | -4.1% | 0.01% | -11.1% |
| Q2 2018 | $576,000 | +169.2% | 43,708 | +178.3% | 0.01% | +125.0% |
| Q1 2018 | $214,000 | +3.4% | 15,708 | -54.9% | 0.00% | 0.0% |
| Q4 2017 | $207,000 | -76.7% | 34,808 | -70.9% | 0.00% | -76.5% |
| Q3 2017 | $888,000 | -24.7% | 119,721 | -5.0% | 0.02% | -32.0% |
| Q2 2017 | $1,180,000 | +69.1% | 126,020 | +31.4% | 0.02% | +78.6% |
| Q1 2017 | $698,000 | -1.7% | 95,921 | 0.0% | 0.01% | 0.0% |
| Q4 2016 | $710,000 | -11.5% | 95,921 | -27.7% | 0.01% | 0.0% |
| Q3 2016 | $802,000 | +18.8% | 132,721 | -11.7% | 0.01% | 0.0% |
| Q2 2016 | $675,000 | +86.5% | 150,321 | +3.4% | 0.01% | +75.0% |
| Q1 2016 | $362,000 | +168.1% | 145,313 | +636.4% | 0.01% | +300.0% |
| Q4 2014 | $135,000 | – | 19,732 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 7,796,516 | $45,142,000 | 7.90% |
| GREAT POINT PARTNERS LLC | 1,000,000 | $5,790,000 | 4.09% |
| Belmont Global Advisors, Inc. | 175,000 | $1,013,000 | 0.82% |
| Broadfin Capital, LLC | 1,033,668 | $5,985,000 | 0.79% |
| WASATCH ADVISORS LP | 2,650,551 | $15,347,000 | 0.15% |
| BALYASNY ASSET MANAGEMENT L.P. | 1,158,613 | $6,708,000 | 0.09% |
| Artal Group S.A. | 275,000 | $1,592,000 | 0.06% |
| STONERIDGE INVESTMENT PARTNERS LLC | 41,355 | $239,000 | 0.05% |
| A.R.T. Advisors, LLC | 33,501 | $193,000 | 0.01% |
| BANQUE PICTET & CIE SA | 50,932 | $295,000 | 0.01% |